These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37606641)

  • 21. Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial.
    Ma CJ; Chang TK; Tsai HL; Su WC; Huang CW; Yeh YS; Chang YT; Wang JY
    Trials; 2019 Dec; 20(1):751. PubMed ID: 31856912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors.
    McNall-Knapp RY; Williams CN; Reeves EN; Heideman RL; Meyer WH
    Pediatr Blood Cancer; 2010 Jul; 54(7):909-15. PubMed ID: 20405511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
    Wagner LM; Perentesis JP; Reid JM; Ames MM; Safgren SL; Nelson MD; Ingle AM; Blaney SM; Adamson PC
    Pediatr Blood Cancer; 2010 Apr; 54(4):538-45. PubMed ID: 20049936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.
    Moreno L; Casanova M; Chisholm JC; Berlanga P; Chastagner PB; Baruchel S; Amoroso L; Gallego Melcón S; Gerber NU; Bisogno G; Fagioli F; Geoerger B; Glade Bender JL; Aerts I; Bergeron C; Hingorani P; Elias I; Simcock M; Ferrara S; Le Bruchec Y; Slepetis R; Chen N; Vassal G
    Eur J Cancer; 2018 Sep; 100():27-34. PubMed ID: 29936064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors.
    Varghese AM; Cardin DB; Hersch J; Benson AB; Hochster HS; Makris L; Hamada K; Berlin JD; Saltz LB
    Clin Cancer Res; 2020 Apr; 26(7):1555-1562. PubMed ID: 31924737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group.
    Vassal G; Couanet D; Stockdale E; Geoffray A; Geoerger B; Orbach D; Pichon F; Gentet JC; Picton S; Bergeron C; Cisar L; Assadourian S; Morland B; ;
    J Clin Oncol; 2007 Feb; 25(4):356-61. PubMed ID: 17264330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
    Hawkins DS; Chi YY; Anderson JR; Tian J; Arndt CAS; Bomgaars L; Donaldson SS; Hayes-Jordan A; Mascarenhas L; McCarville MB; McCune JS; McCowage G; Million L; Morris CD; Parham DM; Rodeberg DA; Rudzinski ER; Shnorhavorian M; Spunt SL; Skapek SX; Teot LA; Wolden S; Yock TI; Meyer WH
    J Clin Oncol; 2018 Sep; 36(27):2770-2777. PubMed ID: 30091945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors.
    Rodriguez-Galindo C; Crews KR; Stewart CF; Furman W; Panetta JC; Daw NC; Cain A; Tan M; Houghton PH; Santana VM
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):15-24. PubMed ID: 16001174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
    Bagatell R; Norris R; Ingle AM; Ahern C; Voss S; Fox E; Little AR; Weigel BJ; Adamson PC; Blaney S
    Pediatr Blood Cancer; 2014 May; 61(5):833-9. PubMed ID: 24249672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group.
    Mascarenhas L; Lyden ER; Breitfeld PP; Walterhouse DO; Donaldson SS; Paidas CN; Parham DM; Anderson JR; Meyer WH; Hawkins DS
    J Clin Oncol; 2010 Oct; 28(30):4658-63. PubMed ID: 20837952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA.
    Anderson P; Ghisoli M; Crompton BD; Klega KS; Wexler LH; Slotkin EK; Stanbery L; Manning L; Wallraven G; Manley M; Horvath S; Bognar E; Nemunaitis J
    Clin Cancer Res; 2023 May; 29(9):1689-1697. PubMed ID: 36780200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies.
    Wang BC; Xiao BY; Lin GH
    BMC Cancer; 2022 Mar; 22(1):349. PubMed ID: 35361149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
    Kim JJ; Ryu MH; Yoo C; Beck MY; Ma JE; Kang YK
    Oncologist; 2019 Nov; 24(11):e1212-e1218. PubMed ID: 31036770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.
    Subbiah V; Braña I; Longhi A; Boni V; Delord JP; Awada A; Boudou-Rouquette P; Sarantopoulos J; Shapiro GI; Elias A; Ratan R; Fernandez C; Kahatt C; Cullell-Young M; Siguero M; Zeaiter A; Chawla SP
    Clin Cancer Res; 2022 Jul; 28(13):2762-2770. PubMed ID: 35486638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors.
    Weekes C; Lockhart AC; Lee JJ; Sturm I; Cleton A; Huang F; Lenz HJ
    Int J Cancer; 2019 Nov; 145(9):2450-2458. PubMed ID: 30958892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium.
    Trippett TM; Herzog C; Whitlock JA; Wolff J; Kuttesch J; Bagatell R; Hunger SP; Boklan J; Smith AA; Arceci RJ; Katzenstein HM; Harbison C; Zhou X; Lu H; Langer C; Weber M; Gore L
    J Clin Oncol; 2009 Oct; 27(30):5102-8. PubMed ID: 19770383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors.
    Venkatramani R; Malogolowkin M; Davidson TB; May W; Sposto R; Mascarenhas L
    PLoS One; 2013; 8(7):e68416. PubMed ID: 23894304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Irinotecan, vincristine, cisplatin, cyclophosphamide, and etoposide for refractory or relapsed medulloblastoma/PNET in pediatric patients.
    Kim H; Kang HJ; Lee JW; Park JD; Park KD; Shin HY; Ahn HS
    Childs Nerv Syst; 2013 Oct; 29(10):1851-8. PubMed ID: 23748464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma.
    Setty BA; Stanek JR; Mascarenhas L; Miller A; Bagatell R; Okcu F; Nicholls L; Lysecki D; Gupta AA
    Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28748602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma.
    Dogan I; Iribas A; Ahmed MA; Basaran M
    J Chemother; 2023 Jul; 35(4):343-347. PubMed ID: 35894948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.